Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
10/2001
10/04/2001WO2001072822A2 Genes involved in intestinal inflammatory diseases and use thereof
10/04/2001WO2001072819A1 A new polypeptide- human gap connexin 9.35 and the polynucleotide encoding it
10/04/2001WO2001072818A1 A new polypeptide- human gap connexin 10 and the polynucleotide encoding it
10/04/2001WO2001072811A1 A new polypeptide-human s4 ribosomal protein 15 and the polynucleotide encoding it
10/04/2001WO2001072805A1 A new polypeptide - human flavoprotein subunit 14.19 and the polynucleotide encoding it
10/04/2001WO2001072804A1 A new polypeptide-human transducin 10 and the polynucleotide encoding it
10/04/2001WO2001072803A1 A new polypeptide- human zinc finger protein 15 and the polynucleotide encoding it
10/04/2001WO2001072802A1 A new polypeptide-human amyloid precursor protein-binding protein 14 and the polynucleotide encoding it
10/04/2001WO2001072800A1 A new polypeptide- human nuclear transforming protein 13 containing atp/gtp binding domain and the polynucleotide encoding it
10/04/2001WO2001072782A2 Immuno-reactive peptide ctl epitopes of human cytomegalovirus
10/04/2001WO2001072779A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
10/04/2001WO2001072777A2 Human transcription factors
10/04/2001WO2001072773A2 Genes isolated from dendritic cells, gene products and methods employing the same
10/04/2001WO2001072758A1 Tricyclic protein kinase inhibitors
10/04/2001WO2001072752A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS
10/04/2001WO2001072749A1 Condensed pyrazole derivatives, process for producing the same and use thereof
10/04/2001WO2001072745A1 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders
10/04/2001WO2001072744A1 N-heterocyclic derivatives as nos inhibitors
10/04/2001WO2001072733A1 Derivatives of p- hydroxy phenyl propionic acid as antiproliferative agents
10/04/2001WO2001072730A1 Selective preventives/remedies for progressive lesions after organ damage
10/04/2001WO2001072728A2 Novel piperazine derivatives
10/04/2001WO2001072723A1 Oxa(thia)zolidine derivative and anti-inflammatory drug
10/04/2001WO2001072717A1 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
10/04/2001WO2001072711A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
10/04/2001WO2001072707A2 Carbamate caspase inhibitors and uses thereof
10/04/2001WO2001072705A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors
10/04/2001WO2001072703A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
10/04/2001WO2001072702A2 Amidino compounds useful as nitric oxide synthase inhibitors
10/04/2001WO2001072669A2 Therapeutic use of polyhydroxy amine derivates
10/04/2001WO2001072334A2 Methods for treating disease with antibodies to cxcr3
10/04/2001WO2001072331A1 Immunostimulating properties of a fragment of tgf-beta
10/04/2001WO2001072329A1 Compositions and methods for enhancing immunogenicity of antigens
10/04/2001WO2001072328A2 Methods of treating diseases with activated protein c
10/04/2001WO2001072325A1 Methods of blocking tissue destruction by autoreactive t cells
10/04/2001WO2001072323A2 Use of insulin for the treatment of cartilagenous disorders
10/04/2001WO2001072305A1 A medicament and method for the production thereof
10/04/2001WO2001072295A2 Compositions and methods for the therapy and diagnosis of lung cancer
10/04/2001WO2001072292A2 Vitamin d compounds used to stabilize kidney transplants
10/04/2001WO2001072290A2 Method for the improvement of islet signaling in diabetes mellitus and for its prevention
10/04/2001WO2001072283A1 Cationic liposomes
10/04/2001WO2001072277A2 Immunotherapeutic methods and compositions
10/04/2001WO2001049688A8 Purine derivatives, process for their preparation and use thereof
10/04/2001WO2001047878A8 Substituted pyrrole mannich bases to combat pain and allergic reactions
10/04/2001WO2001036638A8 Polypeptides and nucleic acids encoding same
10/04/2001WO2001036602A3 Pak5 a member of the p21-activated kinase (pak) protein family, nucleic acids and methods related to the same
10/04/2001WO2001035989A3 Use of anti-idiotypical antibodies as vaccines against cancer
10/04/2001WO2001022990A3 Methods related to immunostimulatory nucleic acid-induced interferon
10/04/2001WO2001022959A3 Compositions comprising progesterone or progesterone analogs for the treatment of inflammatory conditions
10/04/2001WO2001019828A3 Kinase inhibitors as therapeutic agents
10/04/2001WO2001019394A3 Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds
10/04/2001WO2001016319A3 Compositions and methods for the treatment of immune related diseases
10/04/2001WO2001013957A3 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
10/04/2001WO2000047625A9 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
10/04/2001WO2000039279A9 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
10/04/2001WO2000032634A9 Humanized antibodies to gamma-interferon
10/04/2001US20010027207 Modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation; anticarcinogenic, -diabetic, -proliferative and -inflammatory agents; vascular system disorders
10/04/2001US20010027199 Administering a Tumor Necrosis Factor-alpha inhibitor from the group of metalloproteinase inhibitors, quinolones, corticoids, thalidomide, lazaroides, pentoxyphyllines, hydroxamic and carbocyclic acids; spinal disk hernias
10/04/2001US20010027196 Adenosine receptor ligands and their use in the treatment of disease
10/04/2001US20010027184 Serine/threonine protein kinase (H-SGK2)
10/04/2001US20010027175 Inhibiting tumor necrosis factor-alpha (TNF-a) for treating nerve conditions such as sciatica by administering antiinflammatory agent etanercept or infliximab
10/04/2001US20010026932 Agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells; may be useful as antitumor agents
10/04/2001US20010026800 Delivering an immunogen to a preselected region of the gastrointestinal tract
10/04/2001US20010026794 Two heterologous DNA encoding gene products; prolonged half-life
10/04/2001EP1138773A2 Use of plasmids for the manufacture of a composition for vaccine treatment by human and animal
10/04/2001EP1138692A1 Fragments of human chorionic gonadotropin (hcg) as immunoregulator
10/04/2001EP1138680A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
10/04/2001EP1138329A2 Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions
10/04/2001EP1137946A1 Use of vascular endothelial growth factor (vegf)
10/04/2001EP1137792A1 A recombinant vector expressing multiple costimulatory molecules and uses thereof
10/04/2001EP1137783A2 Beta-1,3-galactosyltransferase homologs
10/04/2001EP1137758A2 Method and composition for preserving viruses
10/04/2001EP1137661A1 Procollagen c-proteinase inhibitors
10/04/2001EP1137658A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR $g(a)-INDUCED EXPRESSION OF CELL ADHESION MOLECULES
10/04/2001EP1137656A1 31 human secreted proteins
10/04/2001EP1137652A2 Conjugates comprising galactose alpha 1,3 galactosyl epitopes and methods of using same
10/04/2001EP1137640A1 Cyclic hydrazine derivatives as tnf-alpha inhibitors
10/04/2001EP1137439A2 Stabilization of macrolides
10/04/2001EP1137438A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors
10/04/2001EP1137436A1 Stimulation of t cells against self antigens using ctla-4 blocking agents
10/04/2001EP1137435A2 Adjuvant comprising pulmonary surfactant
10/04/2001EP1137434A2 New cancer treatments
10/04/2001EP1137422A2 Use of human prostate cell lines in cancer treatment
10/04/2001EP1137421A1 Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation
10/04/2001EP1137410A1 Novel 4-dedimethy laminotetra cycline derivatives
10/04/2001EP1137402A1 Phospholipid compositions
10/04/2001EP1137341A1 Baby food stimulating growth of the thymus
10/04/2001EP0891326B1 Novel vitamin d analogues
10/04/2001EP0853614B1 Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
10/04/2001EP0828726B1 Tricyclic inhibitors of matrix metalloproteinases
10/04/2001EP0821691A4 Methods of synthesizing gm2
10/04/2001EP0815123B1 Beta-sheet mimetics and use thereof as protease inhibitors
10/04/2001EP0688314B1 Prodrug derivatives of enzyme inhibitors with hydroxyl groups, methods of preparing them and their use
10/04/2001EP0639979B1 LIGAND FOR THE c-KIT RECEPTOR AND METHODS OF USE THEREOF
10/04/2001CA2429196A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
10/04/2001CA2407036A1 A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide
10/04/2001CA2404669A1 Condensed pyrazole derivatives, process for producing the same and use thereof
10/04/2001CA2404662A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
10/04/2001CA2404626A1 Novel piperazine derivatives
10/04/2001CA2404495A1 Human tap-like protein (transporter associated in antigen processing/presentation)
10/04/2001CA2404493A1 A method for screening for autoimmune disease by identifying polymorphisms in il-12 p40
1 ... 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 ... 1172